Scarica l'app Stockscreener
0.00
100.00%
-0.55
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.55
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$29.96M
Reddito:
$30.99M
Utile/perdita netta:
$-141.41M
Rapporto P/E:
0.00
EPS:
-2.63
Flusso di cassa netto:
$-118.12M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$1.97
Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile
Nome
Marinus Pharmaceuticals Inc
Settore
Industria
Telefono
484-801-4670
Indirizzo
5 RADNOR CORPORATE CENTER SUITE 500, RADNOR, PA
Confronta MRNS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNS
Marinus Pharmaceuticals Inc
|
0.00 | 29.96M | 30.99M | -141.41M | -118.12M | -2.63 |
|
ONC
Beigene Ltd Adr
|
233.37 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.66 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2632 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.54 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.58 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-23 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-08-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-04-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-04-15 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-01-20 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-09-30 | Iniziato | Truist | Buy |
| 2020-07-01 | Iniziato | Cowen | Outperform |
| 2020-07-01 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-09 | Iniziato | Craig Hallum | Buy |
| 2019-12-20 | Iniziato | Oppenheimer | Outperform |
| 2019-03-05 | Ripresa | Jefferies | Buy |
| 2019-02-27 | Downgrade | Mizuho | Buy → Neutral |
| 2019-02-06 | Iniziato | Leerink Partners | Outperform |
| 2018-07-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-03-20 | Iniziato | Mizuho | Buy |
| 2018-02-15 | Iniziato | H.C. Wainwright | Buy |
| 2017-12-14 | Iniziato | Laidlaw | Buy |
| 2016-08-10 | Reiterato | Jefferies | Buy |
| 2016-06-14 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2016-03-08 | Reiterato | Stifel | Buy |
| 2015-12-17 | Iniziato | RBC Capital Mkts | Outperform |
| 2015-11-17 | Iniziato | Jefferies | Buy |
| 2015-10-30 | Reiterato | Oppenheimer | Outperform |
| 2015-08-05 | Reiterato | Oppenheimer | Outperform |
Mostra tutto
Marinus Pharmaceuticals Inc Borsa (MRNS) Ultime notizie
Shareholders that Lost Money on Marinus Pharmaceuticals, Inc. (MRNS) Should Contact Levi & Korsinsky About Pending Class ActionMRNS - ACCESS Newswire
Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by Analysts at StockNews.com - Defense World
Can The RAISE Study Data Give Marinus' Stock A Boost? - RTTNews
FINAL MRNS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS) - Defense World
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Shares Sold by Geode Capital Management LLC - Defense World
JPMorgan Chase & Co. Purchases 354,393 Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Lost Money on Marinus Pharmaceuticals, Inc.(MRNS)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire
StockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS) - Defense World
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc.(MRNS) Shareholders - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Shareholders - ACCESS Newswire
Kiniksa Pharmaceuticals (NASDAQ:KNSA) versus Marinus Pharmaceuticals (NASDAQ:MRNS) Financial Analysis - Defense World
Fragile X Syndrome Market to Show Remarkable Growth Trends from - openPR.com
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus - MarketScreener
Marinus pharmaceuticals director sells shares for $864 - MSN
MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Status Epilepticus Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Marinus Pharma, Pfizer, UCB Biopharma SRL, Sage Therapeutics, Shire - The Globe and Mail
Dravet Syndrome Market Expected to Experience Major Growth - openPR.com
Refractory Status Epilepticus Treatment Market Size in 7MM - openPR.com
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Developmental and Epileptic Encephalopathies Treatment - openPR.com
Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com - Armenian Reporter
MRNS LAWSUIT ALERT: Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRNS - ACCESS Newswire
Long-Term Investors in Marinus Pharmaceuticals, Inc. (NASDAQ: - openPR
Class Action Filed Against Marinus Pharmaceuticals, Inc. (MRNS) Seeking Recovery for Investors – Contact Levi & Korsinsky - ACCESS Newswire
Marinus Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Class Action Filed Against Marinus Pharmaceuticals, Inc. (MRNS) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Marinus Pharmaceuticals director sells shares worth $869 - MSN
Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stock - MSN
Tuberous Sclerosis Complex Therapeutics Market Size Report - openPR
IMMINENT MRNS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com - Defense World
Marinus Pharmaceuticals (NASDAQ:MRNS) Acquisition Completed by Immedica Pharma AB - Defense World
Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stock By Investing.com - Investing.com UK
Immedica Pharma Completes Acquisition of Marinus Pharmaceuticals - TipRanks
Marinus Pharmaceuticals, Inc.Common Stock (NQ: MRNS - FinancialContent
Marinus Pharmaceuticals Inc Azioni (MRNS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):